Analyst firms · Oppenheimer · MRNA

Oppenheimer MRNA price target and rating history

Moderna Inc. (MRNA) · Health Care

Oppenheimer rates Moderna Inc. (MRNA) Perform with a $142 price target, as of its latest action on Sep 13, 2024. It has published 3 rating actions on MRNA since August 2021, including 1 upgrade and 2 downgrades. Across 6 firms with a MRNA price target in the last 12 months, the median target is $57.

Current rating
Perform
Price target
$142
Median target, all firms
$57
Actions on MRNA
3

Every Oppenheimer rating on MRNA

How other firms rate MRNA

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
William BlairMkt PerformOct 27, 2026
CitigroupSell$80Sep 30, 2026
Rothschild & Co RedburnSell$81Sep 3, 2026
Argus ResearchBuy$180Aug 28, 2026
Wolfe ResearchPeer PerformAug 25, 2026
BofA SecuritiesNeutralAug 19, 2026
BarclaysEqual Weight$25Jan 28, 2026
UBSNeutral$34Jan 7, 2026
JefferiesHold$30Dec 12, 2025

Questions about Oppenheimer and MRNA

What is Oppenheimer's price target for MRNA?
Oppenheimer's latest stated price target for Moderna Inc. (MRNA) is $142, from its action on Jan 2, 2024.
What is Oppenheimer's rating on MRNA?
Oppenheimer rates MRNA Perform, a neutral rating, as of Sep 13, 2024.
When did Oppenheimer last change its view on MRNA?
On Sep 13, 2024, Oppenheimer downgrades to Perform from Outperform.
How does Oppenheimer's MRNA target compare with other analysts?
Across 6 firms with a MRNA price target in the last 12 months, the median target is $57.

More MRNA rating histories

All Oppenheimer ratingsMRNA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.